Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Sahlgrenska University Hospital · University of Gothenburg · +5 more institutions
Abstract
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and clinical symptoms, challenges regarding practicality and accessibility hinder their widespread availability and implementation. Consequently, many people with suspected cognitive impairment due to AD do not receive a biomarker-supported diagnosis. Blood biomarkers have the capacity to help expand access to AD diagnostics worldwide. One such promising biomarker is plasma phosphorylated tau (p-tau), which has…
Citation impact
- FWCI
- 41.61
- Percentile
- 100%
- References
- 108
Authors
6- FGFernando González‐OrtizCorresponding
Sahlgrenska University Hospital, University of Gothenburg
- PRPrzemysław R. Kac
University of Gothenburg
- WSWagner S. Brum
Universidade Federal do Rio Grande, Universidade Federal do Rio Grande do Sul, University of Gothenburg
- HZHenrik Zetterberg
Sahlgrenska University Hospital, UK Dementia Research Institute, University College London, University of Gothenburg
- KBKaj Blennow
Sahlgrenska University Hospital, University of Gothenburg
Topics & keywords
- Medicine
- Biomarker
- Clinical trial
- Dementia
- Disease
- Neurology
- Neuroimaging
- Intensive care medicine